ABCL Earnings & Financial Statements
AbCellera Biologics Inc.
$12.02
-$0.81(-6.31%)
66
Overall
--
Value
91
Tech
42
Quality
Market Cap
$4.16B
Volume
8.47M
52W Range
$2.75 - $15.02
Target Price
$16.70
ABCL earnings and financial statements: AbCellera Biologics Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ABCL Annual Financial Statements
| Fiscal year | 2025 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | $75.13M | $38.02M | $489.47M | $375.20M | $233.16M |
| Cost of revenue | - | - | - | $45.52M | $27.14M |
| Operating income | -$217.10M | -$230.43M | $220.56M | $221.90M | $164.35M |
| EBITDA | -$148.77M | -$143.13M | $280.29M | - | - |
| Net income | -$146.41M | -$146.40M | $327.77M | $153.46M | $118.92M |
| EPS (diluted) | $-0.49 | $-0.51 | $0.50 | $0.48 | $0.45 |
| Fiscal year | 2025 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total assets | $1.36B | $1.49B | $1.54B | $1.32B | $1.01B |
| Total liabilities | $390.05M | $285.30M | $307.63M | $292.84M | $175.03M |
| Shareholders’ equity | $966.90M | $1.15B | $1.23B | $1.03B | $830.51M |
| Cash and equivalents | $128.51M | $133.32M | $386.54M | $476.14M | $594.12M |
| Long-term debt | $137.40M | $71.22M | $76.67M | $36.41M | $3.71M |
| Fiscal year | 2025 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating cash flow | -$131.29M | -$43.88M | $277.36M | $244.58M | $22.69M |
| Free cash flow | -$174.07M | -$121.38M | $204.70M | $244.58M | $22.69M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABCL | $12.02 | -6.3% | 8.47M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get AbCellera Biologics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW